[Form 4/A] BIOXYTRAN, INC Amended Insider Trading Activity

Rhea-AI Filing Summary

Bioxytran, Inc. (BIXT) reported an amended insider transaction for Chief Commercial Officer and director Michael Sheikh. On 10/25/2024, he acquired 6,614,720 common shares of Bioxytran at a price of $0.545 per share, reported as an acquisition. After this transaction, he beneficially owned 8,214,720 shares, held directly. The filing explains that these shares were issued as payment for the sale of NDPD Pharma to Bioxytran, meaning the consideration for that business sale was paid in Bioxytran stock rather than cash.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Sheikh Michael

(Last) (First) (Middle)

1905 S AUDUBON CT

(Street)

SPOKANE WA 99224

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOXYTRAN, INC [ BIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CCO

3. Date of Earliest Transaction (Month/Day/Year)
10/25/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)
10/25/2024

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
preferred	10/25/2024		J(1)		6,614,720	A	$0.545	8,214,720	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were issued as payment for the sale of NDPD Pharma to Bioxytran

	Michael Sheikh	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bioxytran (BIXT) report for Michael Sheikh?

Bioxytran reported that Chief Commercial Officer and director Michael Sheikh acquired 6,614,720 common shares of the company on 10/25/2024, at a reported price of $0.545 per share.

Why were 6,614,720 Bioxytran (BIXT) shares issued to Michael Sheikh?

The filing states that the 6,614,720 shares were issued as payment for the sale of NDPD Pharma to Bioxytran, so the seller received Bioxytran stock as consideration.

How many Bioxytran (BIXT) shares does Michael Sheikh own after the transaction?

Following the reported transaction, Michael Sheikh beneficially owned 8,214,720 Bioxytran shares, with ownership reported as direct.

What is Michael Sheikh’s relationship to Bioxytran (BIXT)?

Michael Sheikh is listed as a director, a 10% owner, and an officer of Bioxytran, serving as Chief Commercial Officer (CCO).

What type of SEC form was filed for this Bioxytran (BIXT) transaction?

The transaction was reported on an amended Form 4/A, which discloses changes in beneficial ownership by company insiders such as officers, directors, and large shareholders.

Was the Bioxytran (BIXT) transaction a purchase on the open market?

No. The filing explains that the 6,614,720 shares were issued as payment for the sale of NDPD Pharma to Bioxytran, rather than being bought in an open-market trade.